Dr. Timothy Kristedja is a board-certified internist and oncologist. Dr. Kristedja has is a prolific author based on his extensive research activity. Dr. Kristedja has a B.S. in Biochemistry earned from California Polytechnic State University San Luis Obispo, CA and a M.P.H., Health Services – Management Track from UCLA School of Public Health, Los Angeles, CA. Then he earned his medical degree at Trinity College Dublin, School of Medicine from Dublin, Ireland. His professional training included a residency in Internal Medicine at University of Arizona, Dept. of Medicine, Tucson, AZ and a Fellowship in Hematology and Medical Oncology at Harbor UCLA Medical Center/City of Hope Comprehensive Cancer Center, Torrance, CA and Duarte, CA. At the moment he is serves the California Hematology Oncology Medical Group, Los Angeles, CA as a Hematologist/Oncologist.
Conditions Dr. Timothy Kristedja Treats at Marina Del Rey Hospital
Insurance Accepted
- Aetna
- Medicare
- United Healthcare
Languages Spoken
- English
- Russian
- Spanish
Education & Training
Medical Degree
UCLA School of Public Health Los Angeles, CA M.P.H., Health Services – Management Track
Trinity College Dublin, School of Medicine Dublin
Internship(s)
Residency(ies)
University of Arizona - Internal Medicine
Fellowship(s)
Harbor UCLA Medical Center/City of Hope Comprehensive Cancer Center - Hematology and Medical Oncology
Honors & Awards
Publications & Media
-
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
Boasberg, P.D., Hoon, D.B., Piro, L.D., Martin, M.A., Fujimoto, A., Kristedja, T.S., Bhachu, S., Ye, X., Deck, R.R., O\'Day, S.J.; J Invest Dermatol. 2006-12-01.
-
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O\'Day, S.J., Boasberg, P.D., Piro, L., Kristedja, T.S., Wang, H., Martin, M., Deck, R., Ames, P., Shinn, K., Kim, H., Fournier, P., Gammon, G.; Clin Cancer Res. 2002-09-01.
-
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
O\'Day, S. J., Boasberg, P. D., Kristedja, T. S., Martin, M., Wang, H. J., Fournier, P., Cabot, M., DeGregorio, M. W., Gammon, G.; Cancer. 2001 Aug 01.
